Unternehmen: Ortho-Clinical Diagnostics Inc
LEI 5493006VJVVGE5PD4517, SWIFT ORDIUS33XXX

Ortho-Clinical Diagnostics, Inc. provides solutions for screening, diagnosing, monitoring, and confirming diseases for the transfusion medicine community and laboratories worldwide. It offers integrated clinical chemistry and immunoassay testing systems, chemistry systems, immunodiagnostic systems, and automation solutions that streamline and standardize laboratory workflow. The company also provides donor screening solutions, such as Ortho Summit System, a system for screening assays, automation, and information management; T-cruzi ELISA test system, an enzyme-linked immunosorbant assay for the qualitative detection of antibodies to trypanosoma cruzi in human serum and plasma specimens; and screening assays and information management. In addition, it offers immunohematology products, such as fetal maternal hemorrhage screening test; workstations; ORTHO VISION Analyzer, an interactive analyzer for transfusion medicine laboratories; and ORTHO ProVue that increases productivity with random access, discrete testing, and STAT interrupt. Further, the company offers training and education, and services and support. It also serves hospitals and blood centers. Ortho-Clinical Diagnostics, Inc. was formerly known as Ortho Diagnostic Systems, Inc. and changed its name to Ortho-Clinical Diagnostics, Inc. in 1997. The company was founded in 1974 and is based in Raritan, New Jersey. It has operations in Rochester, New York; Pompano Beach, Florida; Strasbourg, France; and Pencoed, Wales. Ortho-Clinical Diagnostics, Inc. is a former subsidiary of Johnson & Johnson.